Generating stable chinese hamster ovary cell clones to produce a truncated SARS-CoV spike protein for vaccine development

Biotechnology Progress

Volumn 26, Issue 6, 2010, Pages 1733-1740

  Lin, Shih Chang ^a   Leng, Chih Hsiang ^b   Wu, Suh Chin ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

CHO cells expression; SARS CoV; Stable cell clone

Indexed keywords

CELL CLONES; CHINESE HAMSTER OVARY CELLS; CHO CELL; GENE AMPLIFICATION; GLYCOFORMS; MTX SELECTION; SARS-COV; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS; SPIKE PROTEIN; STABLE CELL CLONE; VACCINE DEVELOPMENT;

CELL CULTURE; CLONING; GENE EXPRESSION; PROTEINS;

CLONE CELLS;

MEMBRANE PROTEIN; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CLONE; CHO CELL; CRICETULUS; GENETICS; HAMSTER; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARS CORONAVIRUS;

ANIMALS; CHO CELLS; CLONE CELLS; CRICETINAE; CRICETULUS; MEMBRANE GLYCOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARS VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

CORONAVIRUS; CRICETULUS GRISEUS; SARS CORONAVIRUS; SIMIAN VIRUS 40;

EID: 78650202713     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.480     Document Type: Article

References (28)

1. Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, Rappuoli R. SARS-beginning to understand a new virus. Nat Rev Microbiol. 2003; 1: 209-218.
2. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL. The genome sequence of the SARS-associated coronavirus. Science. 2003; 300: 1399-1404.
3. Yount B, Curtis KM, Fritz EA, Hensley LE, Jahrling PB, Prentice E, Denison MR, Geisbert TW, Baric RS. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA. 2003; 100: 12995-13000.
4. Zhou Z, Post P, Chubet R, Holtz K, McPherson C, Petric M, Cox M. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine. 2006; 24: 3624-3631.
5. He Y, Li J, Heck S, Lustigman S, Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol. 2006; 80: 5757-5767.
6. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7: 226-236.
7. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis. 2005; 191: 507-514.
8. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004; 324: 773-781.
9. Lai SC, Chong PC, Yeh CT, Liu LS, Jan JT, Chi HY, Liu HW, Chen A, Wang YC. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). J Biomed Sci. 2005; 12: 711-727.
10. Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng BJ, Jiang S. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009; 393: 144-150.
11. Zakhartchouk AN, Sharon C, Satkunarajah M, Auperin T, Viswanathan S, Mutwiri G, Petric M, See RH, Brunham RC, Finlay BB, Cameron C, Kelvin DJ, Cochrane A, Rini JM, Babiuk LA. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine. 2007; 25: 136-143.
12. Du L, Zhao G, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun. 2009; 384: 486-490.
13. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA. 2004; 101: 2536-2541.
14. Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, Lanzavecchia A, Baric R. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol. 2008; 82: 3220-3235.
15. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA. 2004; 101: 6641-6646.
16. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA. 2004; 101: 9804-9809.
17. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004; 428: 561-564.
18. Hong WW, Wu SC. A novel RNA silencing vector to improve antigen expression and stability in Chinese hamster ovary cells. Vaccine. 2007; 25: 4103-4111.
19. Mu F, Niu D, Mu J, He B, Han W, Fan B, Huang S, Qiu Y, You B, Chen W. The expression and antigenicity of a truncated spike-nucleocapsid fusion protein of severe acute respiratory syndrome-associated coronavirus. BMC Microbiol. 2008; 8: 207.
20. Chang CY, Hong WW, Chong P, Wu SC. Influence of intron and exon splicing enhancers on mammalian cell expression of a truncated spike protein of SARS-CoV and its implication for subunit vaccine development. Vaccine. 2006; 24: 1132-1141.
21. Chong P, Hsieh SL. U.S. Provisional Application Ser. No. 60/535, 641. 2004.
22. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004; 22: 1393-1398.
23. Marshall E, Enserink M. Medicine. Caution urged on SARS vaccines. Science. 2004; 303: 944-946.
24. Ng SK, Lin W, Sachdeva R, Wang DI, Yap MG. Vector fragment: characterizing vector integrity in transfected clones by southern blotting. Biotechnol Prog. 2010; 26: 11-20.
25. Borys MC, Linzer DI, Papoutsakis ET. Ammonia affects the glycosylation patterns of recombinant mouse placental lactogen-I by chinese hamster ovary cells in a pH-dependent manner. Biotechnol Bioeng. 1994; 43: 505-514.
26. Andersen DC, Goochee CF. The effect of ammonia on the O-linked glycosylation of granulocyte colony-stimulating factor produced by chinese hamster ovary cells. Biotechnol Bioeng. 1995; 47: 96-105.
27. Yang M, Butler M. Effects of ammonia on CHO cell growth, erythropoietin production, and glycosylation. Biotechnol Bioeng. 2000; 68: 370-380.
28. Zhou T, Wang H, Luo D, Rowe T, Wang Z, Hogan RJ, Qiu S, Bunzel RJ, Huang G, Mishra V, Voss TG, Kimberly R, Luo M. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol. 2004; 78: 7217-7226.